Report Detail

Medical Industry Global Orphan Drugs for Adults Market Growth (Status and Outlook) 2022-2028

  • RnM4495274
  • |
  • 15 November, 2022
  • |
  • Global
  • |
  • 113 Pages
  • |
  • LPI(LP Information)
  • |
  • Medical Industry

The global market for Orphan Drugs for Adults is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Orphan Drugs for Adults market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Orphan Drugs for Adults market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Orphan Drugs for Adults market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Orphan Drugs for Adults market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Orphan Drugs for Adults players cover Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA and Novartis, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Orphan Drugs for Adults market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Orphan Drugs for Adults market, with both quantitative and qualitative data, to help readers understand how the Orphan Drugs for Adults market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Orphan Drugs for Adults market and forecasts the market size by Type (Oncology Drugs, Gastrointestinal Drugs and Neurology Drugs), by Application (Hospital Pharmacies, Retail pharmacies and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others

Segmentation by application
Hospital Pharmacies
Retail pharmacies
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Abbvie Inc.
Orpharma
Amgen Inc.
Recordati SpA
Novartis
Celgene
Amryt Pharma Plc.
Johnson & Johnson
GSK Plc.
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals

Chapter Introduction
Chapter 1: Scope of Orphan Drugs for Adults, Research Methodology, etc.
Chapter 2: Executive Summary, global Orphan Drugs for Adults market size and CAGR, Orphan Drugs for Adults market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Orphan Drugs for Adults revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Orphan Drugs for Adults revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Orphan Drugs for Adults market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Orphan Drugs for Adults Market Size 2017-2028
    • 2.1.2 Orphan Drugs for Adults Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Orphan Drugs for Adults Segment by Type
    • 2.2.1 Oncology Drugs
    • 2.2.2 Gastrointestinal Drugs
    • 2.2.3 Neurology Drugs
    • 2.2.4 Cardio-vascular Drugs
    • 2.2.5 Others
  • 2.3 Orphan Drugs for Adults Market Size by Type
    • 2.3.1 Orphan Drugs for Adults Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Orphan Drugs for Adults Market Size Market Share by Type (2017-2022)
  • 2.4 Orphan Drugs for Adults Segment by Application
    • 2.4.1 Hospital Pharmacies
    • 2.4.2 Retail pharmacies
    • 2.4.3 Others
  • 2.5 Orphan Drugs for Adults Market Size by Application
    • 2.5.1 Orphan Drugs for Adults Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Orphan Drugs for Adults Market Size Market Share by Application (2017-2022)

3 Orphan Drugs for Adults Market Size by Player

  • 3.1 Orphan Drugs for Adults Market Size Market Share by Players
    • 3.1.1 Global Orphan Drugs for Adults Revenue by Players (2020-2022)
    • 3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2020-2022)
  • 3.2 Global Orphan Drugs for Adults Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Orphan Drugs for Adults by Regions

  • 4.1 Orphan Drugs for Adults Market Size by Regions (2017-2022)
  • 4.2 Americas Orphan Drugs for Adults Market Size Growth (2017-2022)
  • 4.3 APAC Orphan Drugs for Adults Market Size Growth (2017-2022)
  • 4.4 Europe Orphan Drugs for Adults Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Orphan Drugs for Adults Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Orphan Drugs for Adults Market Size by Country (2017-2022)
  • 5.2 Americas Orphan Drugs for Adults Market Size by Type (2017-2022)
  • 5.3 Americas Orphan Drugs for Adults Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Orphan Drugs for Adults Market Size by Region (2017-2022)
  • 6.2 APAC Orphan Drugs for Adults Market Size by Type (2017-2022)
  • 6.3 APAC Orphan Drugs for Adults Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Orphan Drugs for Adults by Country (2017-2022)
  • 7.2 Europe Orphan Drugs for Adults Market Size by Type (2017-2022)
  • 7.3 Europe Orphan Drugs for Adults Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Orphan Drugs for Adults by Region (2017-2022)
  • 8.2 Middle East & Africa Orphan Drugs for Adults Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Orphan Drugs for Adults Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Orphan Drugs for Adults Market Forecast

  • 10.1 Global Orphan Drugs for Adults Forecast by Regions (2023-2028)
    • 10.1.1 Global Orphan Drugs for Adults Forecast by Regions (2023-2028)
    • 10.1.2 Americas Orphan Drugs for Adults Forecast
    • 10.1.3 APAC Orphan Drugs for Adults Forecast
    • 10.1.4 Europe Orphan Drugs for Adults Forecast
    • 10.1.5 Middle East & Africa Orphan Drugs for Adults Forecast
  • 10.2 Americas Orphan Drugs for Adults Forecast by Country (2023-2028)
    • 10.2.1 United States Orphan Drugs for Adults Market Forecast
    • 10.2.2 Canada Orphan Drugs for Adults Market Forecast
    • 10.2.3 Mexico Orphan Drugs for Adults Market Forecast
    • 10.2.4 Brazil Orphan Drugs for Adults Market Forecast
  • 10.3 APAC Orphan Drugs for Adults Forecast by Region (2023-2028)
    • 10.3.1 China Orphan Drugs for Adults Market Forecast
    • 10.3.2 Japan Orphan Drugs for Adults Market Forecast
    • 10.3.3 Korea Orphan Drugs for Adults Market Forecast
    • 10.3.4 Southeast Asia Orphan Drugs for Adults Market Forecast
    • 10.3.5 India Orphan Drugs for Adults Market Forecast
    • 10.3.6 Australia Orphan Drugs for Adults Market Forecast
  • 10.4 Europe Orphan Drugs for Adults Forecast by Country (2023-2028)
    • 10.4.1 Germany Orphan Drugs for Adults Market Forecast
    • 10.4.2 France Orphan Drugs for Adults Market Forecast
    • 10.4.3 UK Orphan Drugs for Adults Market Forecast
    • 10.4.4 Italy Orphan Drugs for Adults Market Forecast
    • 10.4.5 Russia Orphan Drugs for Adults Market Forecast
  • 10.5 Middle East & Africa Orphan Drugs for Adults Forecast by Region (2023-2028)
    • 10.5.1 Egypt Orphan Drugs for Adults Market Forecast
    • 10.5.2 South Africa Orphan Drugs for Adults Market Forecast
    • 10.5.3 Israel Orphan Drugs for Adults Market Forecast
    • 10.5.4 Turkey Orphan Drugs for Adults Market Forecast
    • 10.5.5 GCC Countries Orphan Drugs for Adults Market Forecast
  • 10.6 Global Orphan Drugs for Adults Forecast by Type (2023-2028)
  • 10.7 Global Orphan Drugs for Adults Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Abbvie Inc.
    • 11.1.1 Abbvie Inc. Company Information
    • 11.1.2 Abbvie Inc. Orphan Drugs for Adults Product Offered
    • 11.1.3 Abbvie Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Abbvie Inc. Main Business Overview
    • 11.1.5 Abbvie Inc. Latest Developments
  • 11.2 Orpharma
    • 11.2.1 Orpharma Company Information
    • 11.2.2 Orpharma Orphan Drugs for Adults Product Offered
    • 11.2.3 Orpharma Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Orpharma Main Business Overview
    • 11.2.5 Orpharma Latest Developments
  • 11.3 Amgen Inc.
    • 11.3.1 Amgen Inc. Company Information
    • 11.3.2 Amgen Inc. Orphan Drugs for Adults Product Offered
    • 11.3.3 Amgen Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Amgen Inc. Main Business Overview
    • 11.3.5 Amgen Inc. Latest Developments
  • 11.4 Recordati SpA
    • 11.4.1 Recordati SpA Company Information
    • 11.4.2 Recordati SpA Orphan Drugs for Adults Product Offered
    • 11.4.3 Recordati SpA Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Recordati SpA Main Business Overview
    • 11.4.5 Recordati SpA Latest Developments
  • 11.5 Novartis
    • 11.5.1 Novartis Company Information
    • 11.5.2 Novartis Orphan Drugs for Adults Product Offered
    • 11.5.3 Novartis Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Novartis Main Business Overview
    • 11.5.5 Novartis Latest Developments
  • 11.6 Celgene
    • 11.6.1 Celgene Company Information
    • 11.6.2 Celgene Orphan Drugs for Adults Product Offered
    • 11.6.3 Celgene Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Celgene Main Business Overview
    • 11.6.5 Celgene Latest Developments
  • 11.7 Amryt Pharma Plc.
    • 11.7.1 Amryt Pharma Plc. Company Information
    • 11.7.2 Amryt Pharma Plc. Orphan Drugs for Adults Product Offered
    • 11.7.3 Amryt Pharma Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Amryt Pharma Plc. Main Business Overview
    • 11.7.5 Amryt Pharma Plc. Latest Developments
  • 11.8 Johnson & Johnson
    • 11.8.1 Johnson & Johnson Company Information
    • 11.8.2 Johnson & Johnson Orphan Drugs for Adults Product Offered
    • 11.8.3 Johnson & Johnson Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Johnson & Johnson Main Business Overview
    • 11.8.5 Johnson & Johnson Latest Developments
  • 11.9 GSK Plc.
    • 11.9.1 GSK Plc. Company Information
    • 11.9.2 GSK Plc. Orphan Drugs for Adults Product Offered
    • 11.9.3 GSK Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 GSK Plc. Main Business Overview
    • 11.9.5 GSK Plc. Latest Developments
  • 11.10 Bristol-Myers Squibb Company
    • 11.10.1 Bristol-Myers Squibb Company Company Information
    • 11.10.2 Bristol-Myers Squibb Company Orphan Drugs for Adults Product Offered
    • 11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Bristol-Myers Squibb Company Main Business Overview
    • 11.10.5 Bristol-Myers Squibb Company Latest Developments
  • 11.11 Roche Holding
    • 11.11.1 Roche Holding Company Information
    • 11.11.2 Roche Holding Orphan Drugs for Adults Product Offered
    • 11.11.3 Roche Holding Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 Roche Holding Main Business Overview
    • 11.11.5 Roche Holding Latest Developments
  • 11.12 Sanofi
    • 11.12.1 Sanofi Company Information
    • 11.12.2 Sanofi Orphan Drugs for Adults Product Offered
    • 11.12.3 Sanofi Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.12.4 Sanofi Main Business Overview
    • 11.12.5 Sanofi Latest Developments
  • 11.13 Takeda
    • 11.13.1 Takeda Company Information
    • 11.13.2 Takeda Orphan Drugs for Adults Product Offered
    • 11.13.3 Takeda Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.13.4 Takeda Main Business Overview
    • 11.13.5 Takeda Latest Developments
  • 11.14 Pfizer
    • 11.14.1 Pfizer Company Information
    • 11.14.2 Pfizer Orphan Drugs for Adults Product Offered
    • 11.14.3 Pfizer Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.14.4 Pfizer Main Business Overview
    • 11.14.5 Pfizer Latest Developments
  • 11.15 Vertex Pharmaceuticals
    • 11.15.1 Vertex Pharmaceuticals Company Information
    • 11.15.2 Vertex Pharmaceuticals Orphan Drugs for Adults Product Offered
    • 11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2020-2022)
    • 11.15.4 Vertex Pharmaceuticals Main Business Overview
    • 11.15.5 Vertex Pharmaceuticals Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Orphan Drugs for Adults. Industry analysis & Market Report on Orphan Drugs for Adults is a syndicated market report, published as Global Orphan Drugs for Adults Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Orphan Drugs for Adults market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,056.10
6,112.20
3,539.22
7,078.44
506,836.80
1,013,673.60
298,473.00
596,946.00
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report